Ahmed Zaki Sabet
Directeur des opérations chez PRECIPIO, INC.
Fortune : 3 166 $ au 30/06/2024
Profil
Ahmed Zaki Sabet is the founder of Precipio Diagnostics LLC, which was founded in 2017.
He holds the title of Chief Operating Officer at Precipio Diagnostics LLC.
Mr. Sabet's current job is Chief Operating Officer at Precipio, Inc., starting in 2018.
Mr. Sabet's former job was Vice President-Operations at Transgenomic, Inc. Mr. Sabet's education history includes an undergraduate degree from New Jersey Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PRECIPIO, INC.
0,04% | 19/04/2024 | 610 ( 0,04% ) | 3 166 $ | 30/06/2024 |
Postes actifs de Ahmed Zaki Sabet
| Sociétés | Poste | Début |
|---|---|---|
| PRECIPIO, INC. | Directeur des opérations | 07/08/2018 |
Precipio Diagnostics LLC
 Precipio Diagnostics LLC Medical/Nursing ServicesHealth Services Precipio Diagnostics LLC operates as a cancer diagnostics reference laboratory. It offers its customers community oncologists and hospitals access to academic institutions and has combined academic-level excellence with the sales and marketing expertise, the proper operational processes and the necessary service level standards required to deliver proper support. The company was founded by Ilan Danieli in 2011 and is headquartered in New Haven, CT. | Fondateur | 01/06/2017 |
Anciens postes connus de Ahmed Zaki Sabet
| Sociétés | Poste | Fin |
|---|---|---|
Transgenomic, Inc.
 Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Directeur des opérations | - |
Formation de Ahmed Zaki Sabet
| New Jersey Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PRECIPIO, INC. | Health Services |
| Entreprise privées | 2 |
|---|---|
Precipio Diagnostics LLC
Precipio Diagnostics LLC Medical/Nursing ServicesHealth Services Precipio Diagnostics LLC operates as a cancer diagnostics reference laboratory. It offers its customers community oncologists and hospitals access to academic institutions and has combined academic-level excellence with the sales and marketing expertise, the proper operational processes and the necessary service level standards required to deliver proper support. The company was founded by Ilan Danieli in 2011 and is headquartered in New Haven, CT. | Health Services |
Transgenomic, Inc.
Transgenomic, Inc. Medical SpecialtiesHealth Technology Transgenomic, Inc. is a global biotechnology company, which provides personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. It operates through the following reportable segments: Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment is a combination of clinical laboratories and pharmacogenomic services business segments. The Clinical Laboratories segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. The Laboratory Services segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies and it employs a variety of genomic testing service technologies, including ICE COLD-PCR technology.The Genetic Assay and Platforms segment includes WAVE System product, which has broad applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. This segment also manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Transgenomic was founded on March 6, 1997 and is headquartered in Omaha, NE. | Health Technology |
